Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: BID

Gene summary for BID

Gene summary.

Gene information	Species	Human
	Gene symbol	BID
	Gene ID	637
	Gene name	BH3 interacting domain death agonist
	Gene Alias	FP497
	Cytomap	22q11.21
	Gene Type	protein-coding
	GO ID	GO:0000082
	UniProtAcc	A8ASI8

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
637	BID	LZE2T	Human	Esophagus	ESCC	4.91e-04	6.56e-01	0.082
637	BID	LZE4T	Human	Esophagus	ESCC	5.17e-10	3.11e-01	0.0811
637	BID	LZE5T	Human	Esophagus	ESCC	3.09e-02	6.36e-01	0.0514
637	BID	LZE7T	Human	Esophagus	ESCC	3.90e-11	8.68e-01	0.0667
637	BID	LZE8T	Human	Esophagus	ESCC	3.16e-07	4.80e-01	0.067
637	BID	LZE20T	Human	Esophagus	ESCC	1.17e-11	4.39e-01	0.0662
637	BID	LZE22D1	Human	Esophagus	HGIN	1.12e-02	9.80e-02	0.0595
637	BID	LZE22T	Human	Esophagus	ESCC	2.26e-02	6.16e-01	0.068
637	BID	LZE24T	Human	Esophagus	ESCC	4.13e-17	6.67e-01	0.0596
637	BID	LZE21T	Human	Esophagus	ESCC	3.07e-05	4.64e-01	0.0655
637	BID	P2T-E	Human	Esophagus	ESCC	6.70e-32	7.10e-01	0.1177
637	BID	P4T-E	Human	Esophagus	ESCC	5.72e-45	1.38e+00	0.1323
637	BID	P5T-E	Human	Esophagus	ESCC	1.50e-63	1.42e+00	0.1327
637	BID	P8T-E	Human	Esophagus	ESCC	1.06e-35	9.84e-01	0.0889
637	BID	P9T-E	Human	Esophagus	ESCC	2.02e-27	8.67e-01	0.1131
637	BID	P10T-E	Human	Esophagus	ESCC	9.82e-44	8.30e-01	0.116
637	BID	P11T-E	Human	Esophagus	ESCC	1.92e-09	4.86e-01	0.1426
637	BID	P12T-E	Human	Esophagus	ESCC	2.40e-27	6.43e-01	0.1122
637	BID	P15T-E	Human	Esophagus	ESCC	1.66e-28	8.13e-01	0.1149
637	BID	P16T-E	Human	Esophagus	ESCC	3.80e-29	7.91e-01	0.1153

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:19057107	Oral cavity	OSCC	positive regulation of membrane permeability	32/7305	48/18723	9.60e-05	7.25e-04	32
GO:00069196	Oral cavity	OSCC	activation of cysteine-type endopeptidase activity involved in apoptotic process	47/7305	78/18723	1.16e-04	8.42e-04	47
GO:005086315	Oral cavity	OSCC	regulation of T cell activation	161/7305	329/18723	1.44e-04	1.02e-03	161
GO:00508527	Oral cavity	OSCC	T cell receptor signaling pathway	68/7305	123/18723	1.80e-04	1.22e-03	68
GO:19021107	Oral cavity	OSCC	positive regulation of mitochondrial membrane permeability involved in apoptotic process	26/7305	38/18723	2.29e-04	1.49e-03	26
GO:000715916	Oral cavity	OSCC	leukocyte cell-cell adhesion	178/7305	371/18723	2.44e-04	1.57e-03	178
GO:00300983	Oral cavity	OSCC	lymphocyte differentiation	179/7305	374/18723	2.74e-04	1.74e-03	179
GO:190303715	Oral cavity	OSCC	regulation of leukocyte cell-cell adhesion	162/7305	336/18723	3.39e-04	2.08e-03	162
GO:19021085	Oral cavity	OSCC	regulation of mitochondrial membrane permeability involved in apoptotic process	29/7305	45/18723	4.85e-04	2.86e-03	29
GO:19021059	Oral cavity	OSCC	regulation of leukocyte differentiation	136/7305	279/18723	5.53e-04	3.21e-03	136
GO:00302175	Oral cavity	OSCC	T cell differentiation	126/7305	257/18723	6.51e-04	3.66e-03	126
GO:20000455	Oral cavity	OSCC	regulation of G1/S transition of mitotic cell cycle	74/7305	142/18723	1.01e-03	5.24e-03	74
GO:002240917	Oral cavity	OSCC	positive regulation of cell-cell adhesion	136/7305	284/18723	1.35e-03	6.62e-03	136
GO:0044346	Oral cavity	OSCC	fibroblast apoptotic process	16/7305	22/18723	1.40e-03	6.79e-03	16
GO:19028064	Oral cavity	OSCC	regulation of cell cycle G1/S phase transition	84/7305	168/18723	2.38e-03	1.05e-02	84
GO:190303910	Oral cavity	OSCC	positive regulation of leukocyte cell-cell adhesion	115/7305	239/18723	2.48e-03	1.09e-02	115
GO:00027646	Oral cavity	OSCC	immune response-regulating signaling pathway	212/7305	468/18723	2.93e-03	1.27e-02	212
GO:005087010	Oral cavity	OSCC	positive regulation of T cell activation	104/7305	216/18723	3.76e-03	1.55e-02	104
GO:00069833	Oral cavity	OSCC	ER overload response	10/7305	13/18723	6.32e-03	2.35e-02	10
GO:19021075	Oral cavity	OSCC	positive regulation of leukocyte differentiation	77/7305	157/18723	6.55e-03	2.43e-02	77

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0501430	Esophagus	HGIN	Amyotrophic lateral sclerosis	140/1383	364/8465	2.13e-25	1.16e-23	9.19e-24	140
hsa0502230	Esophagus	HGIN	Pathways of neurodegeneration - multiple diseases	153/1383	476/8465	1.22e-18	4.41e-17	3.50e-17	153
hsa0501030	Esophagus	HGIN	Alzheimer disease	130/1383	384/8465	5.26e-18	1.71e-16	1.36e-16	130
hsa0493230	Esophagus	HGIN	Non-alcoholic fatty liver disease	66/1383	155/8465	5.21e-15	1.21e-13	9.64e-14	66
hsa0516930	Esophagus	HGIN	Epstein-Barr virus infection	55/1383	202/8465	5.13e-05	6.19e-04	4.92e-04	55
hsa0516730	Esophagus	HGIN	Kaposi sarcoma-associated herpesvirus infection	51/1383	194/8465	2.46e-04	2.69e-03	2.14e-03	51
hsa0421020	Esophagus	HGIN	Apoptosis	36/1383	136/8465	1.67e-03	1.52e-02	1.20e-02	36
hsa0517029	Esophagus	HGIN	Human immunodeficiency virus 1 infection	51/1383	212/8465	2.16e-03	1.90e-02	1.51e-02	51
hsa0541739	Esophagus	HGIN	Lipid and atherosclerosis	51/1383	215/8465	2.95e-03	2.41e-02	1.91e-02	51
hsa0516420	Esophagus	HGIN	Influenza A	42/1383	171/8465	3.41e-03	2.54e-02	2.02e-02	42
hsa0411510	Esophagus	HGIN	p53 signaling pathway	21/1383	74/8465	6.25e-03	4.25e-02	3.37e-02	21
hsa0516330	Esophagus	HGIN	Human cytomegalovirus infection	51/1383	225/8465	7.67e-03	4.63e-02	3.68e-02	51
hsa05014113	Esophagus	HGIN	Amyotrophic lateral sclerosis	140/1383	364/8465	2.13e-25	1.16e-23	9.19e-24	140
hsa05022113	Esophagus	HGIN	Pathways of neurodegeneration - multiple diseases	153/1383	476/8465	1.22e-18	4.41e-17	3.50e-17	153
hsa05010113	Esophagus	HGIN	Alzheimer disease	130/1383	384/8465	5.26e-18	1.71e-16	1.36e-16	130
hsa04932113	Esophagus	HGIN	Non-alcoholic fatty liver disease	66/1383	155/8465	5.21e-15	1.21e-13	9.64e-14	66
hsa05169114	Esophagus	HGIN	Epstein-Barr virus infection	55/1383	202/8465	5.13e-05	6.19e-04	4.92e-04	55
hsa05167114	Esophagus	HGIN	Kaposi sarcoma-associated herpesvirus infection	51/1383	194/8465	2.46e-04	2.69e-03	2.14e-03	51
hsa04210110	Esophagus	HGIN	Apoptosis	36/1383	136/8465	1.67e-03	1.52e-02	1.20e-02	36
hsa05170112	Esophagus	HGIN	Human immunodeficiency virus 1 infection	51/1383	212/8465	2.16e-03	1.90e-02	1.51e-02	51

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

BID

SNV

Missense_Mutation

c.710N>A

p.Arg237Lys

p.R237K

P55957

protein_coding

deleterious(0.01)

benign(0.368)

TCGA-A2-A0CX-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

adriamycin

BID

SNV

Missense_Mutation

c.641N>A

p.Arg214His

p.R214H

P55957

protein_coding

tolerated(0.26)

benign(0.141)

TCGA-AO-A124-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

BID

SNV

Missense_Mutation

c.178N>A

p.Glu60Lys

p.E60K

P55957

protein_coding

deleterious(0)

probably_damaging(0.931)

TCGA-BH-A18G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

BID

insertion

Frame_Shift_Ins

novel

c.385_386insGAATCGGATTAAGGACATCA

p.Ile129ArgfsTer31

p.I129Rfs*31

P55957

protein_coding

TCGA-AR-A1AQ-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

doxorubicin

BID

deletion

In_Frame_Del

rs759487323

c.608_619delAGAAGGTGGCCA

p.Lys203_Ala206del

p.K203_A206del

P55957

protein_coding

TCGA-B6-A0X1-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

BID

SNV

Missense_Mutation

c.146N>A

p.Cys49Tyr

p.C49Y

P55957

protein_coding

deleterious(0.03)

benign(0.001)

TCGA-AA-3492-01

Colorectum

colon adenocarcinoma

Female

>=65

I/II

Unknown

BID

SNV

Missense_Mutation

rs747016844

c.265G>A

p.Glu89Lys

p.E89K

P55957

protein_coding

tolerated(0.09)

benign(0.134)

TCGA-EI-6917-01

Colorectum

rectum adenocarcinoma

Male

<65

III/IV

Chemotherapy

5fluorouracil+oxaciplatina+l-folinian

BID

SNV

Missense_Mutation

rs547322681

c.626C>T

p.Thr209Met

p.T209M

P55957

protein_coding

tolerated(0.35)

benign(0.23)

TCGA-A5-A0G2-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

III/IV

Unknown

BID

SNV

Missense_Mutation

novel

c.350G>T

p.Arg117Ile

p.R117I

P55957

protein_coding

tolerated(0.12)

benign(0.26)

TCGA-AP-A059-01

Endometrium

uterine corpus endometrioid carcinoma

Female

>=65

I/II

Unknown

BID

SNV

Missense_Mutation

rs575351241

c.446N>T

p.Pro149Leu

p.P149L

P55957

protein_coding

tolerated(0.17)

benign(0.068)

TCGA-AP-A1DK-01

Endometrium

uterine corpus endometrioid carcinoma

Female

<65

I/II

Unknown

Page: 1 2 3 4

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1